A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

Exclusion Criteria

• •Diseases or conditions that could interfere with the assessment of safety of the study treatment and compliance of the participant with study visits/procedures, as determined by the Investigator
• •Pregnant or nursing women
• •Active infection in the area that will undergo administration, that the Investigator believes will negatively impact the IP application
• •Known allergy to any of the constituents of the product
• •Concurrent skin transplant or mesh skin grafting; if the participant is currently having transplantation or grafting surgeries they must wait until the transplant has begun to heal and the graft has absorbed prior to initiating B-VEC therapy
• •Participation in an interventional gene therapy clinical trial within the past three (3) months (not including B-VEC administration)